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The generation of reactive oxygen species (ROS) and an altered redox status are common biochemical aspects in cancer cells.
ROS can react with the polyunsaturated fatty acids of lipid membranes and induce lipid peroxidation. The end products of
lipid peroxidation, 4-hydroxynonenal (HNE), have been considered to be a second messenger of oxidative stress. Beyond ROS
involvement in carcinogenesis, increased ROS level can inhibit tumor cell growth. Indeed, in tumors in advanced stages, a further
increase of oxidative stress, such as that occurs when using several anticancer drugs and radiation therapy, can overcome the
antioxidant defenses of cancer cells and drive them to apoptosis. High concentrations of HNE can also induce apoptosis in cancer
cells. However, some cells escape the apoptosis induced by chemical or radiation therapy through the adaptation to intrinsic
oxidative stress which confers drug resistance. This paper is focused on recent advances in the studies of the relation between
oxidative stress, lipid peroxidation products, and cancer progression with particular attention to the pro-oxidant anticancer agents
and the drug-resistant mechanisms, which could be modulated to obtain a better response to cancer therapy.
1. Oxidative Stress and Lipid Peroxidation
A body of evidence suggests that oxidative stress and result-
ing lipid peroxidation are involved in various and numerous
pathological states including inflammation, atherosclerosis,
neurodegenerative diseases, and cancer. The term “oxidative
stress” is frequently used to describe the imbalances in
redox couples such as those reduced to oxidized glutathione
(GSH/GSSG) or NADPH/NADP+ ratios. Such metabolic
disturbances not only involve the overproduction of reactive
free radicals but also occur via a nonfree radical pathway,
for example, by hydrogen peroxide [1]. In such cases, the
products of its action are molecules that are enriched in one
or more oxygen atoms that are generally considered to be
markers of oxidative stress [2].
Reactive oxygen species (ROS) are thought to be the
major ones responsible for the alteration of macromolecules
which is often termed oxidative stress. ROS are generated as
by-products of cellular metabolism, primarily in the mito-
chondria [3] and include free radicals such as superoxide
anion (O2
−•), perhydroxyl radical (HO2•), hydroxyl radical
(•OH), nitric oxide (NO), and other species such as hydrogen
peroxide (H2O2), singlet oxygen (1O2), hypochlorous acid
(HOCl), and peroxynitrite (ONOO−) [4]. The hydroxyl
radical •OH is the most reactive radical that can arise
through the Fenton reaction and the Haber-Weiss reaction
from hydrogen peroxide and metal species (iron, copper)
[5, 6].
To prevent the damage from ROS, cells possess several
antioxidant enzymes such as superoxide dismutases MnSOD
and Cu/ZnSOD, which are located in the mitochondria
and the cytosol, respectively, where they convert superoxide
into hydrogen peroxide [7]. The decomposition of hydrogen
peroxide to water and oxygen is further catalyzed by catalase.
Another antioxidant defense mechanism includes nonen-
zymatic antioxidants such as glutathione (GSH), which
functions in the cellular thiol/disulfide system [8, 9].
The reactive intermediates, produced by oxidative stress,
can alter the membrane bylayers and cause the lipid per-
oxidation of polyunsaturated fatty acids (PUFA) leading
to the formation of lipoperoxyl radical (LOO•), which, in
turn, reacts with a lipid to yield a lipid radical and a lipid
hydroperoxide (LOOH). LOOHs are unstable: they generate
new peroxyl and alkoxy radicals and decompose to secondary
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products [10–12]. Such free radicals produced during lipid
peroxidation have some very local effects, because of their
short life, but the breakdown products of lipid peroxides may
serve as “oxidative stress second messengers,” due to their
prolonged half-life and their ability to diffuse from their site
of formation, compared to free radicals. Those breakdown
products, mostly aldehydes, such as malonaldehyde, hexanal,
4-hydroxynonenal, or acrolein have received a lot of attention
because they are the most reactive compounds [13].
The lipid peroxidation and the breakage of lipids with the
formation of reactive compounds can lead to changes in the
permeability and fluidity of the membrane lipid bilayer and
can dramatically alter cell integrity [5].
Among the products of lipid peroxidation, 4-hydrox-
ynonenal (HNE), is the most intensively studied [13, 14]
since it is a highly electrophilic molecule that easily reacts
with low-molecular-weight compounds, such as glutathione,
with proteins and, at higher concentration, with DNA [15,
16]. Due to its chemical reactivity, this breakdown product
can make covalent modifications on macromolecules and
exert some biological effects. The reactivity of HNE depends
on three main functional groups: the aldehyde group, the
C=C double bond, and the hydroxyl group, which can
participate, alone or in sequence, in chemical reactions with
other molecules [15]. It has been demonstrated that HNE
modifies proteins, either by forming simple Michael adducts
with lysyl, histidyl, and cysteinyl residues [17] or through
Schiff base formation with lysyl residues, leading to pyrrole
formation [18]. In addition, HNE modification can result
in cross-linking of two lysyl residues through reversibly
formed Schiff base Michael adducts [19]. Inside the cells,
the amount of HNE, and of consequence of HNE protein
adducts, represents a steady-state concentration between
the aldehyde produced and that is catabolized. Indeed,
once formed, HNE is rapidly degraded by three major
reactions: reduction to 1,4-dihydroxy-2-nonene by alcohol
dehydrogenases, oxidation to 4-hydroxy-2-nonenoic acid by
aldehyde dehydrogenase, or formation of the glutathione
conjugate (GS-HNE) catalyzed by glutathione S-transferases.
The majority of HNE is metabolized through forming GS-
HNE [20].
2. Levels of Oxidative Stress and Lipid
Peroxidation Products in Cancer Cells
In recent years, it has become evident that compared with
their normal counterparts, many types of cancer cells have
increased levels of ROS [21, 22]. For example, leukaemia
cells freshly isolated from blood samples from patients
with chronic lymphocytic leukaemia or hairy-cell leukaemia
showed increased ROS production compared with normal
lymphocytes [23, 24]. In solid tumours, studies have shown
increased levels of oxidative damage products, such as
oxidized DNA base (8OHdG), which is the most frequently
investigated product, because of its mutagenic character and
the high sensitivity of its immunological detection [25].
The increase in 8OHdG has been demonstrated in thyroid
neoplasia [26], in squamous cell carcinoma [27], in non-
small-cell lung cancer [28], and in prostate cancer cells [29].
A moderate increase in ROS can promote cell pro-
liferation and differentiation [30, 31], whereas excessive
amounts of ROS can cause oxidative damage. Therefore,
maintaining ROS homeostasis is crucial for normal cell
growth and survival. An increase in ROS is associated
with abnormal cancer cell growth and reflects a disruption
of redox homeostasis due either to an elevation of ROS
production or to a decline of ROS-scavenging capacity
[32]. Indeed, the levels of ROS-scavenging enzymes such as
SOD, glutathione peroxidase, and peroxiredoxin have been
shown to be significantly altered in malignant cells [33]
and in primary cancer tissues [34–36], suggesting aberrant
regulation of redox homeostasis and stress adaptation in
cancer cells. The increase of ROS production may depend
on diverse mechanisms, such as the activation of oncogenes,
aberrant metabolism, mitochondrial dysfunction, and loss
of functional p53 [37–39]. Growth factors and cytokines
too stimulate the production of ROS to exert their diverse
biological effects in cancer [40, 41]. Moreover, many cancers
arise from sites of chronic irritation, infection, or inflam-
mation, which is a critical component of tumor progression.
Production of ROS by inflammatory cells as neutrophils and
macrophages is well established, and it represents a mech-
anism to kill tumor cells. For example, tumour-associated
macrophages were shown to induce sublethal oxidative stress
in murine mammary tumour cells, possibly through the
secretion of the inflammatory cytokine tumour necrosis
factor-α (TNF-α) [42]. In neutrophils and macrophages, a
rapid burst of superoxide formation primarily mediated by
NAPDH oxidase leads to subsequent production of hydrogen
peroxide which, in turn, can lead to oxidative stress-induced
cell death [43].
Although an increase of oxidative stress has been demon-
strated in the majority of cancer types, the concentration of
lipid peroxidation products in cancer cells is yet a matter
of debate. First experiments in this field demonstrated
that in the hepatoma cells the level of lipid peroxidation
products was lower than in normal liver cells [44] and
depended on the degree of deviation. According to these
results, Canuto et al. [45] demonstrated that during rat liver
carcinogenesis, the activities of the enzymes metabolizing the
aldehydes increased, thus rendering the cancer cells more
protected against the cytotoxic effect of aldehydes. Moreover,
in hepatoma cells, the major part of HNE is converted
to HNE-GSH conjugate which is rapidly and efficiently
exported out of the cell [46].
The analysis of HNE-protein adducts in different types
of kidney tumors demonstrated that these adducts occur
in kidneys in both normal and tumor cells, although
immunomorphologic analyses suggest less HNE-protein
adducts in tumor cells [47]. In vivo studies on human colon
adenocarcinoma at different TNM and G staging showed
a decrease of HNE in cancer colon biopsies with respect
to normal surrounding tissues [48]. To the contrary, other
experimental results demonstrated that the lipid peroxida-
tion products, malondialdehyde and HNE, were increased in
colorectal cancer tissues [49].
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In thyroid tumors, with a high level of oxidative stress,
both the HNE and 8OHdG content (as a marker of oxidative
stress) was significantly higher than inmatched normal tissue
[50]. Analogously, lipid peroxidation seems to be a com-
mon pathological process in astrocytic and ependymal glial
tumors, in which the incidence of HNE-immunopositive
tumor cells increased with increasing grades of malignancy
[51]. In other tumor types such as the breast cancers at
different degrees of malignancy, 8-OHdG expression dimin-
ished significantly in invasive breast carcinomas compared to
noninvasive lesions; conversely, HNE immunostaining was
strongest in invasive breast carcinomas [52].
These divergent results about the concentration of HNE
in tumors of different origins and the discrepancy between
the level of oxidative stress and the level of products of
lipid peroxidation could have diverse causes: the pattern
of HNE-metabolizing enzymes in the tumor cells, the lipid
composition of the cell membranes with a different level of
peroxidizable substrates, such as PUFA, and the presence of
inflammatory cells, which can increase the level of diffusible
HNE from the tumor surrounding tissues.
However, although the concentration of HNE in the
tumor cells not always correlated with the level of oxidative
stress, in the majority of cancer cells, HNE is a common
denominator in the enhancement of oxidative stress caused
by H2O2, superoxide, UV, heat, and oxidant chemicals such
as doxorubicin [53].
3. Biological Effects of ROS in Cancer Cells
ROS can elicit a broad spectrum of responses depending
on the magnitude of the level, the duration of exposure,
the localization, and the nature of ROS involved [54]. In
general, low levels of ROS are mitogenic and promote cell
proliferation and survival, while intermediate levels cause
transient or permanent cell cycle arrest and induce cell
differentiation [55]. At high levels, ROS can easily react
with membrane lipids, causing an alteration of membrane
permeability; with DNA, causing damage and genomic
instability; with proteins, causing oxidative modifications
which might result in catalytically less active enzymes or
proteins more susceptible to proteolytic degradation. In
this case ROS are detrimental and induce cell apoptosis or
necrosis [56, 57]. On the other hand, when ROS production
does not irreversibly alter cell viability, they can act as a pri-
mary messenger, modulating several intracellular signalling
cascades leading to cancer progression. Indeed, it has been
demonstrated that ROS activate the pathways of mitogen-
activated protein kinases (MAPKs), phosphatidylinositol-3-
kinase (PI3K]/Akt), phospholipase C-g1 (PLCg1), protein
kinase C, nuclear factor-κB (NF-κB), and Jak/Stat [55–59].
Moreover, through distinct signal transduction cascades,
ROS can induce the expression of families of heat shock
proteins, immediate early genes of the bZIP family mem-
bers like c-Jun and c-Fos, hypoxia-inducible factor (HIF),
and antioxidative enzymes which help to regulate redox
homeostasis, the expression of transforming oncoproteins,
and growth factors [54]. ROS have been involved in the
control of cell cycle progression also. Regulation of the
cell cycle requires the precise integration of many different
processes in cells, including the signal transduction cascades
activated by mitogens and the extracellular matrix, the
ubiquitination processes and subsequent degradation of
proteins in the proteasome, and the proper (re-)organization
of the cytoskeleton, in particular actin and tubulin, amongst
many others [60]. Since it has been demonstrated that
ROS influence many of these processes, it is obvious that
ROS influence cell cycle progression [60]. However, in these
studies, most of evidence indicates that the ROS action
leads to a blocking of cell cycle progression. Several studies
have demonstrated that hyperoxia induces inhibition of
proliferation in G1, S, and G2 phases of the cell cycle [61–
63]. A decrease in cell cycle progression due to H2O2 was
also observed in Chinese hamster ovary cells when H2O2
was added to the cells during the M phase [64]. Hyperoxia
(95% O2, 5% CO2) caused an increase in p53 expression
and phosphorylation, p21 mRNA and protein expression
and cell cycle arrest in HCT116 colon carcinoma cells. In
contrast, no effects on p21 expression were observed in
either p53- or p21-deficient cells, indicating the essential
role of p53 in p21-induced cell cycle arrest. Furthermore,
the cells containing p21 were demonstrated to resume
proliferation after recovery, in contrast to p21-deficient cells
[63]. Several studies have demonstrated that ROS caused a
G2/M arrest [65, 66]. In these cases, elevation of ROS was
demonstrated to result in p53-independent accumulation
of p21, an increase in expression of Chk1, and decrease in
Cdc25c. This latter phosphatase causes dephosphorylation
of cdc2 under normal conditions and hence an activation
of the mitotic cyclin-CDK complexes. This effect of ROS
during the G2 phase was accompanied by an increase in
both ERK and p38 phosphorylation [67]. Furthermore, the
effects of ROS on p21, Chk1, and Cdc25d expression were
shown to be dependent on both ERK and p38 activity
[67].
Apparently, both cell proliferation and growth arrest
have been observed after oxidative stress; the cell response
depends on the molecular background of cells and tissues,
the location of ROS production, the concentration of indi-
vidual ROS species, and the antioxidant concentration in the
cells [54]. While the growth arrest induced by a little increase
of oxidative stress may occur in G1, S, or G2 phases and may
be transient, a disproportional increase in intracellular ROS,
achieved with cancer chemotherapy, depletion of cells from
antioxidant proteins, or generation of ROS by immune cells,
can induce a permanent cell cycle arrest, which may end in
senescence and apoptosis. Apoptosis is linked to an increase
in mitochondrial oxidative stress that causes cytochrome
c release and the consequent activation of caspases and
cell death [68, 69]. Additionally, superoxide generation
through the Rac-1/NADPH oxidase pathway can also induce
proapoptotic signalling [70]. Notably, aberrant ROS produc-
tion by dysfunctional mitochondria has also been shown
to increase oxidative-stress-induced cellular senescence [71–
73]. Indeed, ROS can induce cellular senescence by activating
critical cell cycle sentinels that mediate this process, such
as the tumor suppressor proteins p53 and retinoblastoma
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(Rb) [74]. The signal that originates activation of these
checkpoints is the oxidative-stress-induced DNA damage,
such as double-strand breaks, and downstream induction of
cell cycle regulators p21 and p16 to trigger and maintain
senescence/growth arrest [75, 76]. The function mutations
of these critical regulators endow cells with the ability for
unabated proliferation to the point where the telomeres are
critically shortened, a state referred to as “crisis” or mortality
stage 2 (M2) where replication ceases [77]. Oxidative stress
can also provoke the oxidation of telomeric ends, which are
prone to oxidative modification since they are comprised
of sequences that contain triple guanine repeats. Oxidation
of these repeats makes the telomeric ends more susceptible
to breaks and enhances the rate of telomere attrition [78].
Finally, oxidative stress can induce premature senescence by a
direct suppression of telomerase activity, mainly by affecting
the expression of the catalytic subunit of telomerase (hTERT)
[79].
4. Biological Effects of HNE in Cancer Cells
As far as it regards the effect of HNE in cancer cells, the
majority of research reports indicate that HNE added to
cancer cells of diverse origin elicits a reduction of cell prolif-
eration and an induction of apoptosis. The first experiments
were done by using cultivated human leukemic cells, which
have an undetectable level of lipid peroxidation and do not
contain endogenous HNE. In K562 cells, originally derived
from a human erythroleukemia, very low concentrations of
HNE were found to strongly decrease cell proliferation and
to block the expression of the oncogene c-myc, which was
highly expressed in untreated cells [80, 81]. Similarly, in
human HL-60 leukemia cells, HNE strongly decreases cell
proliferation, induces granulocytic-like differentiation, and,
at the same time, blocks the expression of the oncogenes c-
myc and c-myb [82, 83]. The inhibition of c-myc expression
by HNE has also been observed in U937 and ML1 human
leukemic cells and in MEL murine erythroleukemic cells,
in which HNE induced an onset of differentiation also
[84, 85]. These actions of HNE were transient but could be
stabilized by a continuous supply of 1 μM HNE, repeated
10–12 times. Moreover, it has been demonstrated, in colon
cancer cells, a transitory increase in c-myc expression
and a subsequent downregulation, after HNE treatment
[86].
In HL-60 human leukemic cells, the blocking of prolif-
eration caused an increase of the proportion of cells in the
G0/G1 phase of the cell cycle and a corresponding decrease of
S-phase cells. This means that the progression to the S phase
of the cycle in this cell line is prevented by HNE treatment
[87]. In this cell line, the inhibition of cell cycle progression
mostly depends on the inhibition of the cyclin expression, in
particular of cyclins D2, D1, and A [88]. The reduced amount
of G1 cyclins caused a hypophosphorylation of pRb protein
and a consequent blocking of E2F transcriptional activity,
also related to the inhibition of E2F4 expression by HNE
[89, 90]. The effect of HNE on genes involved in the control
of cells cycle progression has been investigated in SK-N-BE
neuroblastoma cells. The aldehyde was shown to be able
to reduce cell-cycle-related transcriptional activity and to
inhibit proliferation in the SK-N-BE neuroblastoma cell line
by increasing the expression of p53 family proteins (p53, p63,
and p73) and p53 target proteins (p21, bax, and G1 cyclins)
[91]. An increase in p53 expression also has been found in
germ cells where HNE treatment inhibited proliferation [92].
Different research groups demonstrated that HNE inhib-
ited proliferation of human colon tumor cells through reg-
ulation of the MAPs kinase pathway [93, 94] or through the
PPAR gamma pathway [86]. Moreover, a strong inhibition
of cell proliferation was reported also in breast cancer
cells (MCF7) treated with conjugated linoleic acid (CLA),
which increases the endogenous levels of HNE [95] and
in human osteosarcoma cells treated with HNE [96]. In
PC3 prostate carcinoma cells, HNE significantly potentiates
the antitumor effects of the HDAC inhibitor panobinostat
(LBH589). Cell cycle analysis revealed that both single
agents and, to a greater extent, their combined treatment
induced G2/M arrest. Furthermore, the combination of
panobinostat and HNE induced significant DNA damage
concomitant with the mitotic arrest [97]. In hepatoma cells,
such as 7777 and J42 hepatomas, the inhibitory effects of
HNE on cell proliferation are lower, probably due to the
presence of a more efficient system removing the aldehydes.
Indeed, these cells display a very high expression of aldehyde
dehydrogenase 3, that is able to destroy a large amount of the
added aldehyde. Its inhibition by antisense oligonucleotide
has strong inhibitory effects on cell proliferation, suggesting
that this aldehyde plays an important role in this inhibition
[98, 99]. In a recent study, performed in SH-SY5Y human
neuroblastoma cells, which can be maintained in an undif-
ferentiated state and can be stimulated to differentiate into
a neuron-like phenotype in cell culture, the susceptibility
to 2,3-dimethoxy-1,4-napthoquinone (DMNQ) and HNE in
differentiated and undifferentiated cells has been compared
[100]. Results demonstrated that differentiated cells were
substantially more resistant to cytotoxicity and mitochon-
drial dysfunction induced by the reactive lipid species HNE
or the reactive oxygen species generator DMNQ and suggest
that profound changes in mitochondrial metabolism and
antioxidant defenses occur upon differentiation of neurob-
lastoma cells to a neuron-like phenotype.
In accordance with these observations are the results
demonstrating that the effects of HNE on normal cell
proliferation were in some cases opposite to that observed
in tumor cells. Concerning the atherogenic role of oxidized
low-density lipoprotein and the lipid oxidation products, it
has been reported that HNE induced vascular smoothmuscle
cell proliferation [101, 102]. More recently, other authors
have shown that the proliferation rate of smooth muscle
cells (SMCs) depends on HNE incubation time and concen-
tration: a prolonged treatment with 0.1 μM HNE resulted
in an increase of cell growth in young SMC but displayed
cytotoxicity in aged SMCs [103]. In the same cell model,
Vindis and collaborators [104] demonstrated that short-term
incubation of SMCs with oxLDLs and HNE induced platelet-
derived growth factor receptor (PDGFR) β activation, while
long-term incubation triggered a desensitization of PDGFR
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to its own agonist, with a progressive inhibition of PDGFR-
β phosphorylation. These authors concluded that PDGFR-
β is a target for HNE, and its progressive inhibition may
contribute to defective SMC proliferation.
A direct comparison between the HNE effect on the
growth of human lymphatic leukemia cells and normal
human peripheral blood lymphocytes has been done by
Semlitsch and collaborators [105], which demonstrated that
HNE showed a cytotoxic effect and reduced DNA synthesis
in lymphatic leukemia cells, whereas it did not show any
significant toxicity on normal lymphocytes. Other important
studies compared the gene expression profile, detected after
treatment of acute myelogenous leukemia (AML) cells with
parthenolide (PTL), with similar signatures in publicly
available gene expression profiles deposited into the Gene
Expression Omnibus (GEO) [106]. PTL was found to be
able to ablate bulk, progenitor, and stem AML cells while
causing no appreciable toxicity to normal hematopoietic
cells, thus the authors hypothesized that other compounds,
able to induce a modification of the gene expression similar
to that produced from PTL, could have similar anticancer
characteristics. The author found 2 new agents, celastrol
and HNE, that had a PTL gene expression signature and
effectively eradicated AML at the bulk, progenitor, and stem
cell level.
Taken together these last data indicates that HNE
strongly reduces the proliferation of tumor cells, but it
increases or does not affect proliferation of normal cells in
relation to the dose of HNE and the time of exposure. This
dual effect may be due not only to the presence of aldehyde-
metabolizing enzymes but also to the antioxidant defenses
and mitochondrial metabolism.
5. Oxidative Stress in Cancer Therapy
Several experimental results demonstrated that the increase
of ROS in cancer cells may play an important role in
the initiation and progression of cancer [107, 108] such
that intrinsic oxidative stress is often viewed as an adverse
event. However, excessive levels of ROS stress can also be
toxic to the cells: cancer cells with increased oxidative stress
are likely to be more vulnerable to damage by further
ROS insults induced by exogenous agents [109]. Therefore,
manipulating ROS levels by redox modulation is a way
to selectively kill cancer cells without causing significant
toxicity to normal cells [110]. In recent years, an increasing
number of experimental results indicated that the increase of
ROS is involved in apoptosis induction by chemotherapeutic
anticancer agents (Figure 1).
5.1. Anticancer ROS-Generating Compounds from Natu-
ral Origin. Several ROS inducing compounds, previously
investigated as antimicrobial agents, pesticides, or natural
products of vegetables, have been demonstrated to possess
anticancer activity in a number of cancer models. A naturally
occurring ROS-inducing compound, rotenone, a natural
hydrophobic pesticide derived from the roots and backs of
the Derris and Lonchocarpus species, has been reported to
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Figure 1: Number of published papers/year, concerning the
oxidative stress in cancer therapy.
display anticancer activity through the induction of apopto-
sis [111–113] in cells derived from human B-cell lymphomas
[113], promyelocytic leukemia [114], and neuroblastomas
[115]. The increase of ROS caused by rotenone is attributed
to irreversible binding and inactivation of complex of the
mitochondrial electron transport chain [114]. This can block
electron transfer from complex to ubiquinone, resulting in
a blockage of the oxidative phosphorylation process and an
increase of ROS. In MCF-7 cells, rotenone caused apoptosis
through a decrease of the antiapoptotic protein, Bcl-2, and
a correspondent increase of the apoptotic protein, Bax. The
pharmacological inhibition of JNK and p38 MAPK revealed
significant protection against rotenone-induced apoptosis,
indicating that the proapoptotic action of rotenone is
mediated by these signaling pathways [116].
Cribrostatin 6 is a quinone-containing natural product
with antimicrobial activity that has been demonstrated
to induce the death of cancer cell lines in culture. Its
mechanism of action involves ROS generation, which has
been indicated as the primary mechanism of cribrostatin 6-
induced apoptosis [117].
D,L-Sulforaphane, a synthetic analogue of naturally
occurring L-isomer, abundant in several cruciferous veg-
etables (e.g., broccoli), is a potent inhibitor of chemically
induced cancer in experimental rodents, and it is also known
to inhibit growth of human cancer cells in association
with cell cycle arrest and reactive oxygen species-dependent
apoptosis [118]. Silibinin, a flavonolignan from the seeds
and fruits of milk thistle (Silybum marianum), is used in
the clinic or as dietary supplements against liver toxicity
in Asia, Europe, and the USA. Although some evidence
indicates an antioxidant activity for silibinin to prevent
hepatotoxicity and other pathogenesis of inflammation,
ischemia/reperfusion, atherosclerosis, and ageing, recent
researches indicate that silibinin induces protective O2
•−
generation in the MCF-7 cell line, and the mitochondrial
respiratory chain complexes I, II, and III are involved in O2
•−
formation [119].
Tanshinone IIA, extracted from the dried root of Salvia
miltiorrhiza (Danshen), is one of the potential candidates
undergoing intensive evaluation, despite its traditional role
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in the treatment of cardiovascular diseases in China. Initial
studies have shown that tanshinone IIA exerted cytotoxic
effect on a number of human tumor cell lines [120]. More
recent studies revealed that induction of apoptosis was the
key factor in contributing to the cytotoxic property of
tanshinone IIA and that this effect is related to induction of
ROS generation [121].
Gallic acid (3,4,5-trihydroxybenzoic acid, GA), a poly-
hydroxy phenolic compound, is abundant in natural plants
such as gallnut, grapes, sumac, oak bark, green tea apple
peels, grapes, strawberries, pineapples, bananas, lemons,
and in red and white wine. Its antioxidative DNA-damage
action has been well documented [122]. However, gallic acid
induces apoptosis in several cancer cell lines by increasing
ROS level and GSH depletion [123].
Phx-3 (2-aminophenoxazine-3-one) is an oxidative phe-
noxazine, like actinomycin D, synthesized by the reactions
of o-aminophenols with bovine hemoglobin. Phx-3 exerts
anticancer activity against various cancer cells “in vitro” and
“in vivo,” promoting both caspase-dependent and caspase-
independent apoptosis [124]. Moreover, Zheng et al. (2010)
reported that Phx-3 might be a strong anticancer drug
against lung cancer, which is intractable to chemotherapy, by
causing various early events, including the decrease of pHi
and ROS production, and finally inducing cellular apoptosis
[125].
Anthocyanidins, a subclass of flavonoids, have been
suggested as useful agents for chemotherapy since they can
trigger apoptosis in human leukemia cell lines through
induction of oxidative stress [126]. Recently, it has been
demonstrated that cyanidin and delphinidin induced apop-
tosis preferentially in drug-resistant LoVo/ADR metastatic
colon cancer cells. This action was accompanied by ROS
accumulation, inhibition of glutathione reductase, and
depletion of GSH [127].
The antitumor agent sesquiterpene lactone parthenolide
shows several biological activities, including inhibition of
NF-kB and STAT3 DNA-binding activity, inhibition of
MAP kinase activity, induction of oxidative stress, and
reduction of GSH, followed by G2/M arrest and apoptosis.
It is the active ingredient of the herb feverfew (Tanacetum
parthenium), which is used orally as a migraine prophylaxis,
and for arthritis, fever, and stomachache. Besides its anti-
inflammatory and antimigraine properties, parthenolide also
shows anticancer activities in a variety of cell lines [128].
Parthenolide modulates multiple targets, thereby contribut-
ing to its various “in vitro” and “in vivo effects.” Nakshatri
et al. reported that parthenolide reverses resistance of breast
cancer cells to tumor necrosis factor-related apoptosis-
inducing ligand through sustained activation of c-Jun N-
terminal kinase [129]. Other authors have demonstrated
that parthenolide induces a robust apoptosis of primary
stem and progenitor acute myeloid leukemia cells thorough
the induction of oxidative stress and inhibits ion of NF-
κB [130]. Inhibition of NF-κB activity, constitutive in many
types of cancers, via either interaction with IKK or more
directly with the p65 subunit of NF-κB, is considered one
of the main mechanisms of its action. At the epigenetic
level, parthenolide reduces HDAC1 level and, by inhibiting
DNMT2 activity, induces global hypomethylation of DNA,
which can restore the expressions of some suppressor genes
[128]. A unique property of parthenolide is its ability to
induce cell deathmainly in cancer cells, while sparing healthy
ones, and it also protects normal cells from UVB and
oxidative stress [128].
Butein, a bioactive flavonoid isolated from numerous
native plants, has been shown to induce apoptosis in human
cancer cells. Recently, it has been reported that the treatment
of neuro-2A neuroblastoma cells with butein decreased the
viability through the increase of intracellular ROS levels
and reduction of the Bcl-2/Bax ratio, triggering the cleavage
of procaspase 3 and poly(ADP-ribose) polymerase (PARP).
Moreover, the pretreatment with the antioxidant agent, N-
acetyl cysteine, blocks butein-induced ROS generation and
cell death [131].
Romidepsin, isolated from Chromobacterium violaceum
(previously called depsipeptide, Kf228, Fr901228), is the
second histone deacetylase inhibitor (HDACi) approved
for the treatment of advanced stages of cutaneous T-cell
lymphoma [132]. HDAC inhibitors lead to a wide spec-
trum of biological effects, including induction of apoptosis
inhibition of angiogenesis, induction of cellular senescence,
and induction of oxidative stress caused by mitochondrial
injury. In particular, for romidepsin, it has been reported
that its apoptotic action is linked to the generation of
hydrogen peroxide and is prevented by N-acetyl-cysteine,
thus suggesting that reactive oxygen species participate in
apoptosis [133].
5.2. Drugs Currently Used in Chemotherapy Acting by ROS
Generation. Many antitumor agents, such as vinblastine,
cisplatin, mitomycin C, doxorubicin, camptothecin, inos-
tamycin, and neocarzinostatin, exhibit antitumor activity via
ROS-dependent activation of apoptotic cell death, suggesting
potential use of ROS as an antitumor agent. Thus, a
unique anticancer strategy named “oxidation therapy” has
been developed by inducing cytotoxic oxystress for cancer
treatment.
Vinblastine belongs to the class of vinca alkaloids which
includes vinorelbine, vincristine, vinblastine, and vindesine.
These substances bind to tubulin as potent inhibitors of
mitotic microtubule polymerization. It has been demon-
strated that vinca alkaloid sequentially induced mitochon-
drial transmembrane potential loss and caspase-dependent
apoptosis. The role played by ROS seems to be essential in
vinca alkaloid-induced aberrant JNK-mediatedMcl-1 down-
regulation and DNA damage followed by mitochondrial
dysfunction-related apoptosis but not in determiningmitotic
arrest [134].
Cisplatin is one of the most commonly used cytotoxic
agents in the treatment of a variety of solid malignant
tumors, for example, in the head and neck, lungs, ovary,
bladder, and testicles. Although treatment with this drug is
often effective, serious side effects such as nausea, nephro-
toxicity, neurotoxicity, and ototoxicity occur often. Several
mechanisms are believed to mediate cisplatin-induced apop-
tosis. The “traditional” mechanism involves covalent binding
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of cisplatin to guanine bases on DNA; the formation of
inter- and intrastrand chain cross-linking; induction of p53,
cell cycle arrest, and apoptosis. More recently, it has been
shown that ROS generated by cisplatin could increase lipid
peroxidation, which alters enzymes and structural proteins
and directs the cell to an apoptotic pathway. Also, cisplatin-
induced apoptosis could involve the inflammatory pathway
[135].
Mitomycin C has been shown to induce apoptosis
through DNA strand breakage and ROS induction [136].
Mitomycin C has been used in treating a wide variety of
cancers including ovarian cancer where it showed activity
in phase II trials. Recently, it has been reported that
tetrathiomolybdate, an anticancer agent acting through the
inhibition of cellular antioxidant copper zinc superoxide
dismutase (SOD1) and through elevation of levels of cellular
ROS, increases the apoptosis induced by mitomycin C
action in ovarian cancer cells. The increased cytotoxicity was
correlated with the activity of ROS, loss of a prosurvival
factor, and the appearance of a proapoptotic marker [137].
Doxorubicin, an anthracycline antibiotic and topoiso-
merase inhibitor, is one of the most widely used and
successful antitumor drugs, but its cumulative and dose-
dependent cardiac toxicity has been a major concern of
oncologists in cancer therapeutic practice for decades [138].
The toxicity toward cardiomyocytes and the induction of
apoptosis in cancer cells are mediated by the direct oxidative
DNA damage leading to indirect H2O2 generation through
PARP and NAD(P)H oxidase activation. DOX caused site-
specific oxidative DNA damage in the presence of copper(II),
which may contribute to apoptosis [139].
Camptothecin, an inhibitor of DNA topoisomerases,
is a plant alkaloid first identified from the Chinese tree,
Camptotheca acuminata. Camptothecin acts on cancer cells
by inhibiting topoisomerase1, an enzyme that covalently
links the tyrosine to the DNA phosphate at the 3′-end
of the broken DNA while generating a 5′-hydroxyl end
at the other end of the break. Two water-soluble camp-
tothecin derivatives are presently approved by the FDA
for IV administration: topotecan and irinotecan. Topotecan
(Hycamtin) is used to treat ovarian cancers and small-cell
lung cancers. However, hematological toxicity is a common
side effect due to the destruction of bonemarrow progenitors
[140]. Camptothecin as well as inhibitors of topoisomerases
induces breaks in the DNA that ultimately lead to pro-
grammed cell death. However, it has been demonstrated
that ROS production is involved in camptothecin-induced
apoptosis. In camptothecin-treated DAOYmedulloblastoma,
cell-reactive oxygen species, especially O2, were elevated, and
the antioxidants glutathione andN-acetyl-cysteine prevented
cell death [141].
Other new ROS-inducing chemicals are under examina-
tion as promising anticancer drugs, such as a naturally occur-
ring ROS-inducing compound, beta-phenyl beta-phenyl
ethyl isothiocyanate, which selectively killed cancer cells but
not normal cells [142]. Another promising compound, NSC-
741909, induces robust ROS generation in sensitive but
not in resistant cancer cells [143]. Celastrol, a triterpene,
shows in acute myeloid cells a pattern of action similar to
that detected for parthenolide and HNE [106]. It facilitates
TRAIL-induced apoptosis by downregulating cell survival
proteins and upregulating death receptors [144]. These
molecules have the potential to be effective for all cancer
cells, although ROS induction through anticancer drugs is
discretely studied and limited to only specific type of cancer
cells. Initial ROS induction seems to be common for many
anticancer agents for most of the cancers.
6. Combined Anticancer Therapies:
Therapy with ROS-Inducing Agents
Besides the intrinsic ROS-generating activity of many anti-
cancer drugs, there is evidence demonstrating an increase of
apoptotic activity when the anticancer drugs were used in
association or in combined treatments with ROS-inducing
agents. In both cases, the cell death was accompanied by
an increase of intracellular ROS. Most experiments have
been performed in particularly aggressive malignance or in
cancers poorly affected by conventional chemotherapy. Some
studies have been performed in pancreatic cancer, which is
one of the most lethal digestive system malignancies and
has a very poor prognosis. In pancreatic cancer cells treated
with MDA-7/IL24 and an ROS inducer (arsenic trioxide or
dithiophene), an increase of apoptosis has been demon-
strated. This effect could be reversed by ROS inhibitors such
as N-acetyl-L-cysteine implying the role of ROS in inducing
cell death in these cells [145]. Another study demonstrated
that the treatment with dihydroartemisinin, a semisynthetic
derivative of artemisinin, with antitumor activity and Apo2
ligand or tumor necrosis factor-related apoptosis-inducing
ligand (Apo2L/TRAIL) increased the apoptotic effect in
human pancreatic cancer cells through reactive oxygen
species-mediated upregulation of DR5 [146]. In pancreatic
and hepatoma cell lines, the use of sorafenib, an inhibitor
of Raf family kinases, and vorinostat, a histone deacetylase
inhibitor, interacts in a synergistic fashion to kill carcinoma
cells by activating CD95. Moreover, low doses of sorafenib
and vorinostat, but not the individual drugs, rapidly
increased ROS, Ca2+, and ceramide levels in gastrointestinal
tumor cells. The authors demonstrated that induction of
cytosolic Ca2+ by sorafenib and vorinostat is a primary event
that elevates dihydroceramide levels, each is an essential
step in ROS generation that promotes CD95 activation
[147]. Another histone deacetylase inhibitor, trichostatin
A, in combined treatment with gemcitabine, a nucleoside
analogue of cytidine (2′,2′-difluorodeoxycytidine; dFdC)
widely used chemotherapeutic regimes for the treatment of
pancreatic cancer, showed a synergistic effect in inhibiting
growth of four pancreatic adenocarcinoma cell lines and
in inducing apoptosis. This effect was associated with the
induction of ROS by gemcitabine, increased expression of
the proapoptotic BIM gene by both trichostatin A and
gemcitabine, and downregulation of the 5′-nucleotidase
UMPH type II gene by trichostatin A [148]. In a panel of
11 different cell lines arising from prostate, breast, lung,
colon, cervix, bladder, and kidney cancers, a combination
therapy of As2O3 with L-buthionine-sulfoximine (BSO),
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which inhibits a critical step in glutathione synthesis, effec-
tively enhanced the “in vitro” growth inhibition effect of
As2O3 alone. Biochemical analysis showed that combined
use of As2O3 and BSO blocked H2O2-scavenging systems
including glutathione, catalase, and glutathione peroxidase,
and that the degree of this blockade was well correlated
with intracellular ROS levels and sensitivity to this treatment
[149]. In eight neuroblastoma cell lines, the increased
inhibition of cell growth induced by combination of MK-
2206, a novel allosteric Akt inhibitor, and rapamycin was
mediated by ROS production [150]. Similarly, in this cell
model, the use of BSO increased the cytotoxic effects of
fenretinide, in neuroblastomamonolayers and spheroids and
in ROS-producing cell lines [151]. In the treatment of hepa-
tocellular carcinoma, the single agent As2O3 was inefficient
for phase II trials, demonstrating that new modalities of
treatment with enhanced therapeutic effect are needed. In
a recent study, Chen et al. [152] showed that oridonin,
a diterpenoid isolated from traditional Chinese medicine
rabdosia rubescens, greatly potentiated apoptosis induced by
As2O3 in hepatocellular carcinoma cells. Moreover, the two-
drug combination enhanced tumor suppression activity in
the murine hepatocellular carcinoma model compared with
single-agent treatment “in vivo.” The synergistic proapop-
totic effect of the combined treatment leads to an increase
in the intracellular reactive oxygen species level, and N-
acetyl-L-cysteine completely blocks this effect. The combi-
nation treatment induced an ROS-dependent decrease in
mitochondrial membrane potential and relocation of Bax
and cytochrome C. In addition, the cotreatment of oridonin
and As2O3 induced ROS-mediated downregulation of Akt
and XIAP and inhibition of NF-κB activation [152]. To treat
hepatocellular carcinoma cells, in association with As2O3,
Poly I : C (polyinosinic acid : polycytidylic acid), an analogue
of dsRNA (double-stranded RNA [153], genistein [154], and
ascorbic acid [155]), has been previously used. In all cases,
a synergistic effect has been observed in inducing apoptosis,
in reducing cell proliferation, and in increasing intracellular
ROS concentration.
In leukemia cells, several reports indicate that combined
therapy, involving the intracellular increase of ROS, can
augment the apoptosis induction. As far as it regards
nonsteroidal anti-inflammatory drugs (NSAIDs), it has been
reported that diclofenac induces growth inhibition and
apoptosis of HL-60 cells through modulation of mitochon-
drial functions regulated by ROS. ROS generation occurs
in an early stage of diclofenac-induced apoptosis preceding
cytochrome c release, caspase activation, and DNA fragmen-
tation. N-Acetyl-L-cysteine suppresses ROS generation, Akt
inactivation, caspase-8 activation, and DNA fragmentation.
The combined treatment with 2-methoxyestradiol, a super-
oxide dismutase inhibitor, significantly enhances diclofenac-
induced apoptosis [156].
In another class of drugs, the histone deacetylase in-
hibitors coadministrated together the alkyl-lysophospholipid
perifosine induce mitochondrial dysfunction (cytochrome
c and apoptosis-inducing factor release), caspase-3 and
-8 activation, apoptosis, and a marked decrease in cell
growth in U937 as well as HL-60 and Jurkat leukemia cells.
These events are associated with inactivation of extracellular
signal-regulated kinase (ERK) 1/2 and Akt, p46 c-jun-
NH2-kinase (JNK) activation, and a pronounced increase
in generation of ceramide and ROS [157]. According to
these results, the treatment with the multiple receptor
tyrosine kinase inhibitor, AEE788, together with the histone
deacetylase inhibitors (LBH589, LAQ824, and trichostatin A)
results in synergistic induction of apoptosis in non-small-
cell lung cancer (MV522, A549), ovarian cancer (SKOV-
3), and leukemia (K562, Jurkat, and ML-1) cells and in
OV202hp cisplatin-resistant human ovarian cancer cells.
AEE788 alone or in combination with LBH589 inactivated
mitogen-activated protein kinase (MAPK) and Akt cascades.
Increased apoptosis is correlated with enhanced ROS gen-
eration. The free radical scavenger N-acetyl-l-cysteine not
only substantially suppressed the ROS accumulation but also
blocked the induction of apoptosis mediated by cotreatment
with AEE788 and LBH589 [158]. A novel therapy against
acute myeloid leukaemia (AML) has been proposed for the
patients over sixty years of age by using the lipid-regulating
drug bezafibrate and the sex hormone medroxyprogesterone
acetate. These compounds showed a potent antileukaemic
activity against AML cell lines and primary AML cells.
Combined treatment of AML cells with bezafibrate and
medroxyprogesterone acetate elevated ROS and delivered the
antineoplastic actions of 15d-prostaglandin J [159].
Niclosamide is a Food and Drug Administration-
approved antihelminthic agent, which inhibits the transcrip-
tion and DNA binding of NF-κB in acute myelogenous
leukemia. It blocked tumor necrosis factor-induced IκB
alpha phosphorylation, translocation of p65, and expres-
sion of NF-κB-regulated genes. Combined treatment with
niclosamide and cytarabine, etoposide, and daunorubicin
shows synergistic activity in inducing apoptosis and in
increasing the ROS level in acute myelogenous leukemia
[160].
In peripheral blood mononuclear cells, isolated from
chemorefractory patients with chronic lymphocytic leuke-
mia, the efficacy and mechanism of action of cisplatinum
in association with fludarabine have been investigated [161].
The two compounds act synergistically in inducing apopto-
sis. The response involved generation of ROS, which led to
specific upregulation of the proapoptotic BH3-only protein
Noxa.
Taken together, these results demonstrated that in mul-
tiple cancer models an increase of oxidative stress leads to
an increase of apoptosis through mechanisms different in
relation to the cell type and the anticancer used. However,
a common feature in all cancers treated with these drug
combinations is the increase of intracellular ROS.
7. Contribution of Lipid Peroxidation
Products in Cancer Treatments
Among the works cited above, which demonstrate the
ROS induction during the treatment with chemotherapeutic
agents, only a small number of reports take into account the
role played by the lipid peroxidation product originated from
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ROS induction. Important evidence is reported by Sturlan
et al. [162], who demonstrated that some polyunsaturated
fatty acids, such as docosahexaenoic acid (DHA), can
sensitize various tumor cells to ROS-inducing anticancer
agents. Apoptotic cell death was preceded by collapse of
the mitochondrial membrane potential, increased expression
of Bax, and caspase-3 activation. The combined effect of
As2O3 and DHA was associated with increased production
of intracellular ROS and toxic lipid peroxidation products
and was abolished by the antioxidant vitamin E or when
oleic acid (a nonperoxidizable fatty acid) was used in place
of DHA. The authors conclude that ROS reduction and toxic
lipid peroxidation products constitute the key mediators
contributing to the combined effect of As2O3 and DHA.
Similar results were obtained in 12 different tumor cell
lines, including MDA-MB-468, SK-BR-3, MCF-7 (breast
cancer), ES-2, SKOV-3 (ovarian cancer), HT-29, SW-620, LS-
174T (colon cancer), PC-3 (prostate cancer), HeLa (cervical
cancer), PANC-1 (pancreatic cancer), and one primary
melanoma cell line resistant to treatment with either As2O3
or DHA alone. These cells, when exposed to As2O3 and
DHA, showed an induction of apoptosis and a concomitant
increase of intracellular lipid peroxidation products. More-
over, the combined effect of As2O3 and DHA was selectively
toxic for malignant cells since no cytotoxic effect was
observed in normal skin fibroblasts, human microvascular
endothelial cells, and peripheral blood mononuclear cells
derived from healthy donors [163]. The toxic effect of the
association of As2O3 and DHA is also observed when other
polyunsaturated fatty acids (PUFAs) (i.e., eicosapentaenoic
acid, arachidonic acid, and gamma-linolenic acid) were
associated to As2O3 in the treatment of fourteen tumor
cell lines. Twelve of 14 As2O3-resistant cell lines tested
were resistant to PUFA monotherapy. However, combined
treatment with As2O3 and either PUFA significantly reduced
cell viability in a dose-dependent manner with AA being the
most potent As2O3 enhancer. The combined cytotoxic effect
of combined treatment was due to induction of apoptosis,
preceded by increased intracellular aldehyde products of
lipid peroxidation and was abolished by the antioxidant
vitamin E. These effects were selectively toxic for malignant
cells, and no cytotoxic effect was observed in normal
skin fibroblasts and human microvascular endothelial cells
[164].
A potent antileukaemic activity has been observed by
using the combination of the lipid-regulating drug bezafi-
brate and the sex hormone medroxyprogesterone acetate
against AML cell lines and primary AML cells. It has been
reported that, beside the ROS increase, an increase of lipid
peroxidation products also occurs [159].
In colon cancer cells, the combined treatment with 5-
fluorouracil and resveratrol (trans-3,4′,5-trihydroxystilbene)
results in a significant decrease in long-term cell survival and
an imbalance in cellular antioxidant activities, leading to a
significant increase in the levels of both intracellular ROS
and lipid peroxides. Combined treatment with resveratrol
sensitizes colon cancer cells to 5-fluorouracil, inducing a
further increase in oxidative stress, which was linked to the
inhibition of AKT and STAT3 proteins, which are known to
have oncogenic potential in colorectal carcinomas [165]. A
paramount role of lipid peroxidation of PUFAs not only in
carcinogenesis but also in potential therapeutic strategy on
colorectal cancer has been recently outlined in the review
by Cai et al. [166]. The authors conclude that since the end
products of lipid peroxidation, such as malondialdehyde and
HNE, have a cytotoxic effect not only in normal cells but also
in cancer cells, PUFAs may play a potential role in colorectal
cancer treatment.
Our research group recently demonstrated that HNE
significantly potentiates the antitumor effects of the HDAC
inhibitor panobinostat (LBH589) in the PC3 prostate cancer
cell model. Panobinostat and HNE inhibit proliferation of
PC3 cells, and the combination of the two agents results in
a significant G2/M arrest and cell death which occurs after
the combined treatment only. Furthermore, HNE and, to a
greater extent, the combined treatment induce dephosphory-
lation of Cdc2 leading to progression into mitosis. Moreover,
our results showed that the combination of panobinostat
and HNE induced significant DNA damage concomitant
with the mitotic arrest [167]. Previously, we demonstrated
that PPAR-alpha ligands (clofibrate and ciprofibrate) and
PPAR-gamma ligands (troglitazone and 15d-prostaglandin
J2) inhibit growth and induce monocytic differentiation in
HL-60 cells, andHNE, which alone induces granulocytic-like
differentiation of HL-60 cells, potentiates the monocytic dif-
ferentiation induced by ciprofibrate, troglitazone, and 15d-
prostaglandin J2. Moreover, HNE treatment significantly
inhibits U937 cell growth and potentiates the inhibition of
cell growth in PPAR-gamma ligand-treated cells [168].
8. Radiation Therapy, ROS Generation,
and Lipid Peroxidation Induction
The most important physical stimulus that causes ROS is
ionizing radiation (IR). IR is one of the main treatment
modalities used in the management of cancer, and it can
evoke a series of biochemical events inside the cell. These
events comprise many important cellular processes, such
as DNA damage and repair, apoptosis, cell cycle control,
signal transduction, and oxidative stress response [169]. The
IR effects include damage of DNA, lipids, and proteins
by the energy of radiation, and by the ROS derived from
intercellular water. The secondary response involved signal
transduction and gene expression. Among these effects,
ROS induced by IR are crucial in inducing cell death. The
mechanisms of ROS induced by IR involved in apoptotic cell
death and cell cycle arrest have been widely investigated in
the field of cancer radiotherapy. The response to radiation
depends on the type and dose of radiation, tissue sensitivity,
and intracellular factors that include position in the cell cycle,
oxygen concentration, and levels of antioxidants. Radiation
in the presence of high oxygen concentration increases the
amount of oxygen free radicals and makes free radical-
induced damage permanent. In the absence of oxygen,
damage produced by the indirect action can be repaired.
Oxygen modifies the indirect, but not the direct action
of radiation. Antioxidants reduce free radicals and repair
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damage, maintaining integrity of normal cells and affecting
tumor cells to a lesser extent [170].
The deleterious cellular effects by ROS include DNA
damage and membrane oxidative damage. The formation
of single- and/or double-stranded breaks of DNA resulted
in cell cycle arrest and recruitment of DNA repair enzymes
to rescue cells from the damage. Beyond DNA damage,
another major target of radiation and ROS is believed to
be the membranes of cytoplasmic organelles and plasma
membrane of cells. It is observed that membrane lipids are
easily peroxidised by ROS produced by IR, causing structural
and functional impairment [171–174]. Oxidative damage
leads to an alteration in the both lipid bilayer fluidity and
permeability properties. In the context of cellular response
to radiation, the contributions of radiation oxidative damage
to membranes as well as to DNA damage via ROS appears
rather complex, and these initiators pathways of cytotoxicity
seem to be intimately linked in the development of radiation
induced cell death. Moreover, lipid peroxidation induced
by IR leads to the production of aldehydes which, in
turn, may contribute to apoptosis induction and cell cycle
arrest.
Although the presence of reactive aldehydes derived from
lipid peroxidation after IR has been long demonstrated,
a few studies have investigated the role played by these
end products in inducing IR effects. In prostate cells, the
relationship between IR treatment, ROS production, lipid
peroxidation, glutathione (GSH) levels, and DNA damage
of the human benign prostate hyperplasia BPH-1 cell line,
and two prostate cancer cell lines, LNCaP, which is androgen
sensitive, andDU-145, which is androgen nonresponsive, has
been investigated [175]. The authors demonstrated that DU-
145 cells were characterized by higher DNA damage, more
evident extent of lipid peroxidation, and lower levels of ROS
and GSH compared to BPH-1 or LNCaP. These results could
suggest that the increase of lipid peroxidation, more than the
ROS production, is responsible for DNA damage. Another
recent study in PC3 prostate cancer cells injected into nude
BALB/c mice demonstrated that the radiotherapy efficacy of
prostate cancer can be increased with pro-oxidant, and the
reduction of tumor size is proportional with the increase of
lipid peroxidation [176].
By using docosahexaenoic acid (DHA), a 22-carbon
omega-3 PUFA with 6 cisdouble bonds highly susceptible to
peroxidation induced by oxidative stress, in association with
IR, Kikawa et al. demonstrated a decrease in cell proliferation
and an induction of cell death accompanied by an increase
of lipid peroxidation in A549 lung adenocarcinoma cells
[177]. In the same cell model, Dittmann et al. found that the
radiation-induced src activation and EGFR stabilization can
be mimicked by addition of HNE. The radiation-generated
HNE is bound to EGFR and src and correlated with complex
formation following radiation [178]. The authors suggest a
scenario, where radiation-induced lipid peroxidation results
in generation of HNE. HNE activates the redox-sensitive
switch of src, which results in a conformational alteration
associated with increased kinase activity. Activated src phos-
phorylates EGFR at Y845 and caveolin 1 at Y14, which
leads to internalization of EGFR into caveolae and transports
into nucleus. Nuclear EGFR regulates DNA-PK activity and
supports DNA-repair processes [179].
In diverse cell models such as Ehrlich ascites, human
cervical, and breast cancer cells, the cytotoxic effects of
phytochemicals which increase lipid peroxidation, in com-
bination with ionizing radiation, have been demonstrated
[180], suggesting that modulation of membrane peroxidative
damage and intracellular ROS may help achieve efficient
killing of cancer cells which may provide a new approach
to developing effective treatment of cancer. According to
these results, other authors demonstrated that the addition
of omega-3 PUFAs can enhance the radiosensitivity of
LS174T, CO112, and Caco-2 colon cancer cells, in terms of
cell growth, survival, and apoptosis [181]. The addition of
omega-3 PUFAs induced a dose-dependent additive decrease
in cell survival after irradiation via apoptosis induction.
Moreover, the formation of lipid peroxidation products
and modulation of cyclooxygenase II activity seemed to be
involved, because coincubation with vitamin E abolished the
effect.
9. Oxidative Stress and Lipid
Peroxidation Products in Cancer Chemo-
and Radioresistance
Although the idea of inducing preferential cancer cell
death by an ROS-mediated mechanism showed promising
therapeutic activity in experimental and clinical studies,
some cancer cells, especially those in advanced disease stages,
have become highly adapted to intrinsic oxidative stress with
upregulated antioxidant capacity. This redox adaptation not
only enables the cancer cells to survive under increased ROS
stress, but also provides a mechanism of resistance to many
anticancer agents and radiation therapy [182]. It has been
demonstrated that preexposure of normal epithelial cells to
low but continuous levels of exogenous oxidants confers
cellular resistance to subsequent oxidative stress even at a
higher level [183]. Since cancer cells actively produce high
levels of ROS and are consistently exposed to such endoge-
nous oxidants, it is possible that the intrinsic oxidative stress
may exert a selective pressure and increase the population of
cells that are capable of stress adaptation [184, 185]. Those
cells that survive oxidative stress are likely to have acquired
adaptive mechanisms to counteract the potential toxic effects
of elevated ROS and to promote cell-survival pathways [186]
(Figure 2). Additionally, the generation of endogenous ROS
in combination with the drugs which initially induces ROS
production may contribute to a decrease in the sensitivity to
these drugs in long-term treated cancer cells. Indeed, it has
been observed that cisplatin or chlorambucil, which initially
induces ROS production in ovarian carcinoma A2780 cells,
after prolonged drug treatment with either drug actually
reduces the ROS level making those cells resistant to the drug
[187, 188]. Thus, a decrease of ROS level in prolonged drug-
treated cells is not a secondary cellular outcome; instead, it is
a primary mechanism for specified drug resistance.
Chemoresistance and radioresistance in cancer are the
major obstacles to successful application of cancer therapy.
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Figure 2: ROS level in normal, cancer, and chemo- and radio-resistant cancer cells. Under physiological conditions, normal cells maintain
redox homeostasis with a low level of basal ROS by controlling the balance between ROS generation (pro-oxidants) and elimination
(antioxidant capacity). Normal cells can tolerate a certain level of exogenous ROS stress owing to their “reserve antioxidant capacity.”
The antioxidant reserve can prevent cell transformation and cell death. In cancer cells, the increase in ROS generation from metabolic
abnormalities and oncogenic signallingmay trigger a redox adaptation response, leading to an upregulation of antioxidant capacity, high ROS
generation, and elimination to maintain the ROS levels below the toxic threshold. A further increase of ROS stress and in lipid peroxidation
products in cancer cells (black space) using exogenous ROS-modulating agents or lipid peroxidation substrates is likely to cause elevation of
ROS above the threshold level, leading to cell death. This might constitute a biochemical basis to design therapeutic strategies to selectively
kill cancer cells using ROS-mediated mechanisms. Finally, excessive increase in intracellular ROS levels (and in lipid peroxidation products)
as mediated by radiation therapy and chemotherapeutics may be repulsed by the tumour cells through an increase in the expression of
endogenous antioxidants. This redox adaptation not only enables the cancer cells to survive under increased ROS stress, but also provides a
mechanism of resistance to many anticancer agents and radiation therapy.
Elevation of certain transcription factors, antioxidants, and
survival signals as a result of redox adaptation probably
explains the drug-resistant phenotype [189, 190]. Moreover,
the inflammatory tumor microenvironment can modulate
not only cancer development but also cancer responsiveness
and resistance to conventional anticancer therapies [191].
Experimental studies have led to the identification of
various cancer cell-intrinsic resistance mechanisms, for
example, activation and/or overexpression of drug trans-
porter proteins (e.g., P-glycoprotein), altered expression
of detoxifying enzymes (e.g., glutathione S-transferase), or
resistance to apoptosis/senescence pathways [192–195]. In
addition, several chemotherapeutic agents, such as pacli-
taxel, vinblastine, vincristine, doxorubicin, daunomycin,
5-fluorouracil, cisplatin, and tamoxifen, have also been
shown to activate the transcription factor NF-κB [196–198].
The NF-κB is one of the major chemoresistance-related
antiapoptotic factors. Many human cancers possess high
levels of the constitutive NFκB activity, which can be further
induced by some anticancer drugs. High NFκB activity
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links inflammation and tumourigenesis [199]. Activated
NF-κB triggers a series of molecular reactions including
upregulation of antiapoptotic protein-encoding genes [200]
that induce cancer chemoresistance. High NF-κB activity has
been identified in drug-resistant cancer cells, and ectopic
overexpression of NF-κB can block anticancer drug-induced
apoptosis [201]. Overexpression of p50 and p65, the two
subunits of NF-κB, results in increased NF-κB activity and
induces 5-fluorouracil and gemcitabine resistance [201, 202].
In most cancers, cell resistance is associated with activa-
tion of prosurvival pathways, such as NF-E2-related factor 2
(Nrf2) [203] or elevated glutathione (GSH) levels [204]. For
example, some studies demonstrated that in DOX-resistant
human colon cancer cells (HT-29-DX), the level of GSH is
higher than that in HT-29 chemosensitive cells [205].
Furthermore, recent work suggests that the transcription
factor Nrf2 is responsible for resistance to the GSH-depleting
agent BSO, and abrogation of Nrf2 in combination with BSO
seemed to be an effective therapeutic strategy [206].
Nrf2 protein serves as a sensor of chemical- and
radiation-induced oxidative and electrophilic stress [207].
Nrf2 resides predominantly in the cytoplasm where it inter-
acts with actin-associated cytosolic protein, Keap1 (Kelch-
like ECH-associated protein 1, also known as Nrf2 inhibitor,
INrf2), which inhibits the Nrf2 activity. Under oxidative
stress, Keap1 releases Nrf2 which translocates in the nucleus.
The mechanisms by which Nrf2 is released from Keap1
under stress have been actively investigated. A consensus has
emerged that oxidative/electrophilic stress modification of
Keap1Cys-151 followed by PKCδ-mediated phosphorylation
of Nrf2Ser-40 leads to the release and stabilization of
Nrf2 [207]. In the nucleus, Nrf2 coordinately activates the
transcription of a battery of cytoprotective proteins leading
to reduced apoptosis, enhanced cell survival, and increased
drug resistance. This is achieved through Nrf2 binding to
antioxidant response element (ARE) present in the promoter
regions of cytoprotective genes including glutathione S-
transferases [208]. The overexpression of glutathione S-
transferases (GSTs), enzymes that catalyze the conjugation of
reduced glutathione to electrophilic compounds, may reduce
the reactivity of various anticancer drugs [209]. GSTs are
also responsible for the resistance toward HNE injury after
treatment with butyrate in colon cancer cells [210].
Several reports indicate that Nrf2 activity increases the
chemoresistance of cancer cells. Lau et al. demonstrated a
strong positive correlation between Nrf2 levels and resistance
of three cancer cell lines to chemotherapeutic drugs such
as cisplatin, doxorubicin, and etoposide [211]. According to
these findings, the role of Nrf2 in determining the efficacy
of cisplatin was also demonstrated in ovarian cancer cells
using small interfering RNA knockdown of Nrf2 [212].
Moreover, the stable overexpression of Nrf2 resulted in
enhanced resistance of cancer cells to chemotherapeutic
agents including cisplatin, doxorubicin, and etoposide.
Inversely, downregulation of the Nrf2-dependent response
by overexpression of Keap1 or transient transfection of Nrf2-
small interfering RNA (siRNA) rendered cancer cells more
susceptible to these drugs [213]. Downregulation of Keap1,
consequent to gene mutations or loss of heterozygosity in
the Keap1 locus, has been identified in lung cancer cell lines
or cancer tissues and results in an upregulation of Nrf2
and in transactivation of its downstream genes [214]. We
recently demonstrated that increased Nrf2 activity resulted
in a reduction of HNE sensitivity in prostate cancer cells and
that the inhibition of Nrf2 expression with specific siRNA
resulted in a reduction in GST A4 expression and GS-HNE
formation, indicating that Nrf2 controls HNE metabolism
[215].
Nrf2 is also involved in radioresistance. Indeed, ionizing
radiation activates the Nrf2 antioxidant response [216],
and it has been established that the constitutive activation
of Nrf2 protects against ionizing radiation toxicity and
confers radioresistance in mouse embryonic fibroblasts
[217]. In a recent work, Lee et al. demonstrated that the
inhibition of Nrf2-binding activity and expression by 4-(2-
Cyclohexylethoxy aniline, IM3829) inhibit the increase of
the Nrf2 target genes induced by treatment with tertiary
butylhydroquinone or radiation. Combined treatment with
IM3829 and radiation significantly inhibited clonogenic
survival of H1299, A549, and H460 lung cancer cells,
suggesting that the blocking of Nrf2-dependent antioxidant
responses could be a promising strategy for increasing the
radiosensitivity of human lung cancer [218].
Other mechanisms involved in the drug resistance
regard the transport of xenobiotics and their metabo-
lites by ATP-binding cassette (ABC) transporters particu-
larly P-glycoprotein (Pgp) and the multidrug resistance-
associated protein (MRP1), which have been extensively
studied during the last decade [219]. A link between Nrf2,
multidrug-resistant proteins (MRPs), and HNE has been
demonstrated by Mahaffey et al. [220]. MRPs can be
increased by chemotherapy, radiation, and other xenobiotic
stresses although the underlying mechanism remains largely
unknown. Since HNE has been established to cause the
activation of the Nrf2-EpRE signaling and cytoprotec-
tive gene induction [221] and the MRP3 induction was
dependent upon the transcription factor Nrf2 [220], the
HNE upregulation of MRP3 mRNA and protein levels in
cell lines with wild-type Keap1, but not in the Keap1-
mutant NSCLC cell lines, supports the hypothesis that
MRP3 induction by HNE involves Nrf2 activation. Another
mechanism of chemo- and radioresistance involves RLIP76.
It has been demonstrated that the protein RLIP76, which
is a nonABC, GTPase-activating protein, functions as an
alternative transporter of the end products of detoxification
pathways such as glutathione conjugates and xenobiotics.
RLIP76 may act in parallel with ABC transporters, or
it may be the predominant pump in certain cell types
or situations [222]. It has been suggested that RLIP76
plays a major role in the mechanisms of drug resistance
[223]. Indeed, in K562 human myelogenous leukemia cells,
RLIP76 overexpression confers a broad resistance to multiple
chemotherapy drugs including cisplatin, melphalan, dox-
orubicin, daunorubicin, vincristine, vinblastine, vinorelbine,
and mitomycin-C [224]. Conversely, inhibition of RLIP76
by polyclonal antibodies causes increased drug accumulation
and increased cytotoxicity. RLIP76 plays an important role in
the transport of HNE, too. Sharma et al. demonstrated that
ISRN Oncology 13
RLIP76 mediates active transport of GS-HNE, according to
previous results showing that RLIP76-mediated efflux of GS-
HNE regulated the intracellular concentration of HNE and
thereby affected HNE-mediated signaling [225]. The role of
RLIP76 in radioresistance has been outlined by the study in
RLIP76(−/−) and RLIP76(+/+) C57B mice. RLIP76(−/−)
mice were significantly more sensitive to radiation than
the wildtype, and the levels of HNE and GS-HNE were
significantly increased in RLIP76(−/−) tissues [226].
Recent studies in the field of chemo- and radioresistance
regard the cancer stem cells (CSCs) or cancer-initiating
cells, which are a group of cells with self-renewal and
differentiation capacity. CSCs are believed to be the cause of
chemo- and radioresistance and disease recurrence in many,
if not all, types of cancer [227]. Although the redox status
of cancer stem cells is not well characterized, it has been
suggested that cancer stem cells share low level of ROS [228].
It has been demonstrated that breast cancer stem cells are
more tumorigenic and are relatively resistant to radiation at
the DNA and cellular levels, due to significantly lower levels
of basal and radiation-induced ROS in these cells, indicative
of higher levels of ROS scavengers [229]. Human gastroin-
testinal cancer stem cells with a high level of CD44 expression
showed an enhanced capacity of GSH synthesis and defense
against ROS by a cysteine-glutamate exchange transporter
[230]. Diehn et al. (2009) reported that ROS levels are lower
in human and murine breast cancer stem cells compared
to nonstem breast cancer cells [231]. In general, breast
cancer stem cells display an upregulation of ROS-scavenging
molecules that maintain ROS levels to be low, thereby
contributing to tumor radioresistance. In a recent report,
Cipak et al. demonstrated that HNE and hydroxyl radical-
modified collagen cause growth suppression of human
breast carcinoma stem cells [232]. In looking specifically
at leukemic stem cells (LSCs), several reports suggest the
possibility of eradicating LSCs by increasing the ROS level.
Guzman et al. (2005) showed that parthenolide induces
apoptosis of LSCs in acute myelogenous leukemia (AML)
and blast crisis chronic myelogenous leukemia (CML) by
increasing ROS levels [233]. Ito et al. (2008) demonstrated
an important role of the promyelocytic leukemia protein
(PML) tumor suppressor in the maintenance of quiescent
CML stem cells, introducing the possibility of eradicating
CML stem cells with arsenic trioxide (As2O3) [234], an ROS
generator that inhibits PML. Not only ROS inducers have
been considered for eradicating leukemic stem cells, but also
HNE has been suggested as a new agent able to effectively
eradicate AML at the bulk, progenitor, and stem cell level
[106], indicating that the modulation of the redox systems
in cancer stem cells is now an active area of research, as it is
critical that we begin to develop strategies to eradicate these
specific cell populations.
10. Concluding Remarks
In recent years, it has become evident that targeting oxidative
stress levels and the products of breakdown of polyunsat-
urated fatty acid is a feasible therapeutic approach that
may improve therapeutic selectivity and overcome drug
resistance. Numerous agents, that can interfere with redox
cell signaling pathways, have been identified, demonstrating,
in preclinical models, selective toxicity toward the cancer
cells, with increased endogenous ROS, raising oxidative
stress over the threshold of toxicity. Association of chemical
or radiation therapies with pharmacological agents that
have pro-oxidant properties or are able to induce lipid
peroxidation increases the effectiveness of the treatment. The
increased intracellular antioxidant capacity is a common
phenomenon in tumor cells resistant to many anticancer
agents and radiation. In these cells, the use of agents to
abrogate such adaptation mechanisms in combination with
conventional chemotherapy or radiotherapy can improve
therapeutic outcomes. Analogous results have been obtained
in cancer stem cells, which as well as the chemo- and
radioresistant tumor cells have high level of antioxidant
capacity.
The potential of using a redox-modulating strategy
to eliminate malignant cells without killing normal cell
represents a new therapeutic strategy even if a more detailed
understanding of ROS-mediated signaling in tumor cells and
in tumor stem cells is necessary to develop the therapeutic
intervention to selectively kill cancer cells and overcome drug
and radiation resistance.
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